Overview

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Status:
Withdrawn

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label Phase I trial designed to determine the phase 2 recommended dose (RP2D) of belinostat in combination with nivolumab with or without ipilimumab.

Phase:

Phase 1

Details

Lead Sponsor:

University of Utah

Collaborators:

Acrotech Biopharma
Acrotech Biopharma LLC
Bristol-Myers Squibb

Treatments:

Belinostat
Ipilimumab
Nivolumab